Harbour BioMed, a global biopharmaceutical company committed to the discovery and development of novel antibody therapeutics, and Evinova, a global health-tech company, have entered a strategic collaboration in artificial intelligence (AI).

Under the terms of the collaboration, Harbour BioMed and Evinova China will jointly apply AI and digital technologies to enhance the efficiency of innovative biologics development. Building on their respective strengths, the two companies aim to build an open ecosystem for AI-driven drug R&D.

Dr. Jingsong Wang, Founder, Chairman and CEO of Harbour BioMed, stated, “We are pleased to collaborate with Evinova to advance the application of AI in biotherapeutic development. Harbour BioMed has built a robust and differentiated product pipeline based on our industry-leading Harbour Mice technology platform. Through this collaboration, we look forward to applying AI to improving clinical study efficiency and accelerating the delivery of innovative therapies to patients around the world.”

Nate Zhang, General Manager of Evinova China, stated, “Evinova leverages the digital transformation insights of top global pharmaceutical companies to design our AI-powered clinical development solutions and digital strategy consulting services, so that we can accelerate the delivery of better health outcomes. To realize our mission, Evinova China needs to partner with innovative companies like Harbour BioMed, which are rooted in China while harboring global ambitions. Together, through our world-class AI technology platforms and deep therapeutic expertise, we can help take China-originated breakthrough assets from the laboratory to the world.”